A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy (NCT07771465)
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
🩺 Plain-English Summary (8th-Grade Level)
Danicamtiv is an investigational medication, which means it is still being studied and has not been approved. The purpose of this study is to learn how well danicamtiv works, how safe it is, how well people can take it when used in patients with genetic or familial dilated cardiomyopathy (DCM). There are currently no approved medicines made specifically to treat genetic or familial DCM.
Who can join: Review the eligibility criteria below.
Location: University of Alabama Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (78 Sites)
Showing the first 25 of 78 sites.
- University of Alabama Birmingham — Birmingham, Alabama
- Cedars Sinai — Los Angeles, California
- University of California, Los Angeles (UCLA) - David Geffen School of Medicine — Los Angeles, California
- University of California, San Diego (UCSD) - Medical Center — San Diego, California
- University of California, San Francisco (UCSF) — San Francisco, California
- Stanford University Medical Center — Stanford, California
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
- Mayo Clinic - Jacksonville — Jacksonville, Florida
- Northwestern University — Chicago, Illinois
- Louisiana State University (LSU) Health Sciences Center — New Orleans, Louisiana
- Johns Hopkins Medicine — Baltimore, Maryland
- Brigham and Women's Hospital — Boston, Massachusetts
- Henry Ford Health System — Detroit, Michigan
- University of Minnesota — Minneapolis, Minnesota
- Mayo Clinic - Rochester — Rochester, Minnesota
- Saint Luke's Mid America Heart Institute — Kansas City, Missouri
- Washington University in St. Louis — St Louis, Missouri
- University of Nebraska Medical Center — Omaha, Nebraska
- NYU Langone Health — New York, New York
- Columbia University Medical Center/ New York Presbyterian Hospital — New York, New York
- Duke University Medical Center — Durham, North Carolina
- The Lindner Center for Research and Education at The Christ Hospital — Cincinnati, Ohio
- The Ohio State University Wexner Medical Center — Columbus, Ohio
- Oregon Health & Science University (OHSU) — Portland, Oregon
- University of Pennsylvania — Philadelphia, Pennsylvania
📞 Contact the Study Coordinator
Phone: (877) 310-5135
Email: clinicaltrials@kardigan.bio
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Symptomatic Genetic Dilated Cardiomyopathy (DCM) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.